Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs

por Lepper, Alisa, Bitsch, Rebekka, Özbay Kurt, Feyza Gül, Arkhypov, Ihor, Lasser, Samantha, Utikal, Jochen, Umansky, Viktor
Publicado 2023

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients

por Petrova, Vera, Groth, Christopher, Bitsch, Rebekka, Arkhypov, Ihor, Simon, Sonja C. S., Hetjens, Svetlana, Müller, Verena, Utikal, Jochen, Umansky, Viktor
Publicado 2023

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice

por Bitsch, Rebekka, Kurzay, Annina, Özbay Kurt, Feyza, De La Torre, Carolina, Lasser, Samantha, Lepper, Alisa, Siebenmorgen, Alina, Müller, Verena, Altevogt, Peter, Utikal, Jochen, Umansky, Viktor
Publicado 2022

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2

por Özbay Kurt, Feyza Gül, Lepper, Alisa, Gerhards, Catharina, Roemer, Mathis, Lasser, Samantha, Arkhypov, Ihor, Bitsch, Rebekka, Bugert, Peter, Altevogt, Peter, Gouttefangeas, Cécile, Neumaier, Michael, Utikal, Jochen, Umansky, Viktor
Publicado 2022

HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling

por Arkhypov, Ihor, Özbay Kurt, Feyza Gül, Bitsch, Rebekka, Novak, Daniel, Petrova, Vera, Lasser, Samantha, Hielscher, Thomas, Groth, Christopher, Lepper, Alisa, Hu, Xiaoying, Li, Wei, Utikal, Jochen, Altevogt, Peter, Umansky, Viktor
Publicado 2022